A B S T R A C T Platelets in patients with storage pool disease are markedly deficient in a nonmetabolic (storage) pool of ADP that is important in platelet aggregation. They are also deficient in ATP, although to a lesser degree. In seven patients with this disorder, including one with albinism, platelet 5-hydroxytryptamine (5-HT) levels were reduced in proportion to the reduction in ATP (r = 0.94). Their platelets show diminished capacity to absorb ["C] 5-HT, and the type of defect was similar to that produced in normal platelets by reserpine, a drug known to inhibit the uptake of 5-HT by the platelet dense granules. Storage pool-deficient platelets also converted more [8H] 5-HT to [3H] 5-hydroxyindoleacetic acid than did normal platelets, and the platelets in one of two patients studied contained increased amounts of 5-HT metabolites. The above findings, together with those reported previously, support the conclusion that the capacity of the dense granules (which may be either diminished or functionally abnormal) for storing 5-HT is decreased in storage pool disease; as a result, the 5-HT that enters the platelet may be more exposed to monoamine oxidases present on mitochondrial membranes. This diminished storage capacity (for 5-HT) may also explain why preincubating platelet-rich plasma with 5-HT for 45 min without stirring inhibits subsequent platelet aggregation by 5-HT to a greater degree in patients with storage pool disease than in normal subjects. The latter finding is also consistent with the theory that the aggregation of platelets by 5-HT is mediated by the same receptors on the plasma membrane that are involved in its uptake. The diminished release of platelet-bound ["C]5-HT by collagen that we found in these patients, as well as findings in previous studies, suggests that the release reaction may also be abnormal in storage pool disease.
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INTRODUCTION
The 5-hydroxytryptamine (5-HT, serotonin)1 present in blood is found in the platelets (1) and originates from enterochromaffin cells, particularly those in the gastrointestinal tract (2) . The transfer of 5-HT from plasma to platelets can occur at a considerable concentration gradient (3) , and at least two -subcellular sites have been implicated in this transport mechanism. There is evidence that active transport of 5-HT through the platelet membrane (4) may be mediated by specific receptors that appear to be of the classical D-type (5) . Within the platelets, 5-HT is stored in granules of high electron density (dense bodies) (6) (7) (8) (9) , and it has been suggested that the localization of 5-HT within these granules may protect it from the action of metabolizing enzymes (10) . In particular, platelets contain monoamine oxidase (11) , (presumably located on the external membrane of mitochondria), and the formation of the principal metabolites of 5-HT, 5-hydroxytryptophol and 5-hydroxyindoleacetic acid (5-HIAA) (10, 11) , is considerably enhanced if the platelets are treated with reserpine, a drug that liberates 5-HT from its storage organelles (10) (11) (12) (13) . Platelets are also aggregated by 5-HT (14) , and recent studies by Baumgartner and Born suggest that 5-HT-induced platelet aggregation is mediated by the same receptors responsible for its uptake at the plasma membrane (15) (16) (17) .
The platelet dense granules that store 5-HT also contain appreciable amounts of bivalent cations (18) , as well as a special metabolically inactive pool of adenine nucleotides (the storage pool) that is important in platelet aggregation (19) (20) . We have previously reported a group of patients with a congenital disorder of hemostasis in whom the contents of the platelet dense granules are diminished (21) (22) (23) . As a result of the diminished amounts of ADP in the storage pool, collagen-induced platelet aggregation is impaired, and the second phase of epinephrine and ADP-induced aggregation is either absent or diminished (24) (25) (26) (27) . In addition, the release mechanism may also be abnormal in these patients (28) . The type of congenital defect present in the platelets of these patients with "storage pool disease" makes them uniquely suitable for studying certain aspects of 5-HT uptake, metabolism, and release, and 5-HT-induced aggregation.
METHODS Patients
The study included six patients with storage pool disease.
Three patients (E. P., L. G., and S. N.) are unrelated, while three others (D. C., S. C., and R. C.) are members of a previously described family (family C) (25) . In previous studies, all patients showed diminished collageninduced platelet aggregation and absent or diminished second-phase aggregation with epinephrine or ADP (24) (25) (26) (27) . In addition, the amounts of storage pool ADP and ATP in their platelets were diminished (21, 22) . Platelet 5-HT levels were decreased in three patients (L. G., D. C., and S. N.), and normal in one patient (E. P.) (22) . The levels were not measured in patients R. C. and S. C. In the latter study, the normal levels of platelet 5-HT were 126 ±31.6 nmol/10' platelets. A unique phospholipid abnormality, consisting of an increased lecithin: phosphatidyl ethanolamine ratio, was also found in family C but not in the other unrelated patients (29) . Through the courtesy of Dr. James A. Wolff, we also studied a 10-yr-old girl (S. M.) of Puerto Rican descent with oculocutaneous albinism (30), on whom some of the findings at age 2 have been previously reported (31) . She has light blonde hair, and the color of her skin is considerably lighter than that of her parents or siblings. Her irises are blue-grey, and continuous coarse nystagmus was prominent. She has continued to show easy bruising, frequent epistaxis, and excess bleeding after tooth extractions. Our studies showed a platelet count of 233,000/mm8, absent second wave of aggregation with 5 uM epinephrine, markedly diminished collageninduced aggregation (4%, compared with normal [±2 SD] values of 73±16% obtained with a dilute suspension of collagen [25, 26] ), and disaggregation, after normal initial aggregation, with 4 /M ADP.
Control subjects were normal hospital employees. Both control subjects and patients took no drugs for at least 1 wk before the study.
Blood
Venous blood was mixed with 3.2% (0.108 M) sodium citrate (9:1) and centrifuged at 1,500 g and 20'C for 3 min to obtain platelet-rich plasma (PRP). To obtain platelet-poor plasma (PPP), the blood was centrifuged at 2,400 g for 30 min at 4°C. All 
Measurement of 5-HT in platelets
The method used was a modification of the method of Crosti and Luchelli (33, 34) as previously described, (22) , except that in the present study fluorescence was measured in an Aminco-Bowman spectrofluorometer with excitation at 295 nm and emission at 540 nm, whereas in the previous study In most studies, we also measured the radioactivity in the platelet pellet directly. This was done by resuspending the pellet in 1 ml of PPP containing 1% Triton X-100 and counting the radioactivity as described above. When measured in this way, the calculated percent uptake of radioactive 5-HT into platelets was generally 1-5% lower than when calculated by the first method, in which it was assumed that all of the loss of radioactivity from the plasma could be accounted for by uptake into the platelets. This was observed in both normal subjects and in patients.
Collagen-induced release of platelet-bound agents parallels that of endogenous 5-HT and therefore can be used to assess the platelet release reaction (35) . In this study, we used a suspension of human connective tissue, undiluted or diluted 1: 2 in saline and prepared as previously described (36) , as a source of collagen. .04 for all specimens. After incubation, 4 ml PRP was centrifuged at 12,000 g and 40C for 10 min. The platelet pellet and 2 ml of the supernatant plasma were extracted with 2 ml and 1 ml of 1 M HCl04, respectively, for 10 min at 40C, and the protein precipitates were sedimented by centrifugation at 20,200 g for 5 min. 1.5 ml of each supernate was then treated with either 1.5 ml (pellet supernate) or 0.5 ml (plasma supernate) of 0.6 M K2CO3 to bring the pH to 7.4 and to remove C104-. The KClO4 was sedimented by high speed centrifugation for 5 min, and the neutralized extracts were mixed (1: 1) with a standard solution (37) that contained 5-HT (Sigma), 5-HIAA (Sigma), and 5-hydroxytryptophol, (Regis Chemical Co., Morton Grove, Ill.) in concentrations of 1 mM. The extract-standard mixtures were stored at -60°C.
Paper chromatography. The above extracts were thawed, 20-,gl aliquots were spotted under nitrogen on Whatman no. 1 chromatography paper (1 X 10-in strips) and the indoles were separated by ascending chromatography for 6 h in the dark with isopropanol: H20: concentrated am- 5-HT, and organic phase, containing 5-HIAA and 5-hydroxytryptophol, obtained after extraction of the acidic supernates into ethyl acetate (see above) were determined in 3 N HCl by the spectrofluorometric method described in a previous section. The amount of metabolite was expressed as the percent of the total 5-hydroxyindoles. There was a good correlation (r = 0.94) between the amounts of 5-HT and ATP in the platelets (Fig. 1) . Aggregation of platelets by 5-HT and by a mixture of 5-HT and epinephiine. As reported by others (14, 15), we found that 5-HT produces weak aggregation of human platelets, consisting of a single, reversible wave. However, the aggregation of platelets by 5-HT is markedly increased by the simultaneous addition of epinephrine in concentrations that, by themselves, produce only a small first wave (15, 16) . We therefore used a mixture of 5-HT (final concentration 5 uM) and epinephrine (final concentration 1 /LM) to aggregate platelets in this study. The velocity (V) of the first wave of aggregation produced by this mixture of 5-HT and epinephrine will henceforth be referred to as 5-HT (epinephrine)-induced platelet aggregation. We confirmed the findings of Baumgartner and Born that 5-HT (epineph-rine) -induced platelet aggregation was diminished by prior incubation without stirring with 5-HT (15, 16) . This inhibitory effect of 5-HT was dose-dependent and progressive during the first 5-10 min of incubation (Fig. 2) . With continued incubation (except for the highest concentration of 5-HT), the platelets gradually regained their ability to aggregate with 5-HT (epinephrine).
We next studied whether the behavior of platelets in storage pool disease was similar to that described above in normal subjects. We incubated PRP with increasing concentrations of 5-HT (0.1-5.0 /AM) for 45 min at 370C and then studied 5-HT (epinephrine)-induced platelet aggregation. The results are shown in Fig. 3 and demonstrate that for each concentration of 5-HT used during the 45-min incubation period, the subsequent aggregation of storage pool platelets by 5-HT (epinephrine) (VHT) was less, relative to the control value, Vo, than that obtained with normal platelets. The results of these studies indicate that the inhibition of 5-HT (epinephrine)-induced aggregation by prior incubation of the platelets with 5-HT, first described by Baumgartner and Born (15, 16) , is more apparent in patients with storage pool disease than in normal subjects.
Uptake of radioactive 5-HT into platelets. PRP was incubated with ["C] 5-HT, as described in Methods.
The uptake of radioactivity into the platelets of normal subjects was rapid during the first 5-10 min, and saturation levels of 95±2 (SD)% uptake were obtained after 30 min (Fig. 4) . In five patients with storage pool disease, the saturation levels (but not the initial rates of uptake) were decreased (Fig. 4) . The most pronounced abnormalities were observed with the platelets of patient S. N. and in the patient (S. M.) with albinism.
The shape of the 5-HT uptake curves in patients with storage pool disease were similar to those produced by incubating normal PRP with varying concentrations of reserpine, a drug that inhibits the uptake of 5-HT into the platelet granules (40) (41) (42) . Reserpine had no effect on the initial rate of uptake, but decreased the saturation levels of ["C]5-HT (Fig. 5) . By contrast, imipramine, a membrane-active drug (40, 43) rate of uptake, but the platelets continued to accumulate 5-HT during the incubation period (Fig. 5) . A 2-ml sample was then stirred in the aggregation module for 6 min with 0.1 ml of either undiluted or diluted (1: 2) collagen and the amount of released radioactivity (expressed as a percent of the amount taken up by the platelets) was determined. The solid bars depict the mean+±SD values obtained in normal subjects. Individual values are those obtained in patients with storage pool disease (-) and in two normal subjects (N1 and N2) who had ingested 1.2 g of aspirin 2 h before their blood was obtained (X). along the dashed lines, and the radioactivity in the strips was eluted and counted (see Table I ). Radioactivity in zone 3 could be either an unidentified metabolite or trailing from the adjacent 5-HT zone.
ratio of the total amount of 'H metabolites (in platelets and plasma) to that of [ Table I ). These studies were not done in patient S. M.
DISCUSSION
The diagnostic features of storage pool disease are the markedly diminished content of platelet ADP and the relatively lesser diminution of ATP, resulting in an increased ATP/ADP ratio (Fig. 1) . As discussed in detail previously (22, 47) , these findings are due to the deficiency of a special, nonmetabolic pool of adenine nucleotides (the storage pool) that in normal platelets has a particularly high content of ADP. We found a decreased content of platelet 5-HT in all seven patients with storage pool disease studied, and the levels showed a good correlation with those obtained for ATP. The latter finding is consistent with previous suggestions that 5-HT and ATP in platelets are complexed, withbivalent cations, as high molecular-weight aggregates (18, 48, 49) . In contrast to the striking decrease in ADP obtained in all patients, the extent to which 5-HT and ATP were decreased was more variable (Fig. 1) .
The most striking decreases were obtained in the patient S. M. with albinism. Decreased 5-HT (31, 50, 51) and adenine nucleotide (50) values have also been reported in other patients who have both albinism and a bleeding disorder, and the findings in the present study suggest that the platelet defects (31, (50) (51) (52) in these patients may differ only in degree from those in patients with "idiopathic" storage pool disease. In addition to the diminished levels of 5-HT and adenine nucleotides, the platelets of patients with storage pool disease and albinism are also deficient in Ca" ' (23) and show diminished numbers of the electron-dense granules (51, 53) in which these substances are stored (6-9). As also described in patients with albinism (31, 50) , their platelets showed an impaired capacity for absorbing radioactive 5-HT, and the type of defect appeared to be similar to that observed in normal platelets treated with reserpine, a drug that specifically blocks the incorporation of 5-HT into the platelet granules (40) (41) (42) . These findings suggest that the basic defect in storage pool disease may be either a decreased number of the dense granules or a functional defect in their storage capacities. An impaired capacity of the dense granules for storing 5-HT would appear to provide the most satisfactory explanation for the diminished 5-HT content of their platelets.
The findings in the present study further suggest that the platelet 5 It is not clear why increased amounts of radioactive metabolites of 5-HT were not found in the three members of family C who were studied. Other differences between the platelet defects in this family and those in other, unrelated patients with storage pool disease have been previously noted (26, 27) . In addition to an increased metabolism of ['H] 5-HT, we also found increased amounts of endogenous 5-HT metabolites in the platelets of patient E. P. (S. M. was not studied in this regard). Future studies to detect a possible increase in the urinary excretion of 5-HT metabolites in patients with storage pool disease are anticipated. The increased capacity for metabolizing platelet 5-HT in storage pool disease is best explained at present by the diminished capacity of their platelets for accumulating and sequestering 5-HT in storage granules. As a result of this latter defect, a relatively larger percentage of the 5-HT transported through the plasma membrane may remain unprotected from monoamine oxidase present on mitochondrial membranes.
The impaired release of platelet-bound ["C] 5-HT by collagen that we found in storage pool disease could be due to a relatively smaller percentage of the absorbed 5-HT entering the storage granules, if the latter are the source of the 5-HT extruded from the cell during the release reaction (54) . However, in previous studies we found that the release of heparin-neutralizing activity (platelet factor 4, PF-4) by collagen or epinephrine was also impaired in storage pool disease (28) , although the total content of PF-4 in their platelets was normal, and Hardisty et al. reported that the thrombin-induced release of acid hydrolases was decreased in the albinism variant of this syndrome (50) . In addition, synthesis of prostaglandins E2 and F2., which is closely associated with the release reaction (55) , is also impaired in storage pool disease (56) . These findings suggest that the release mechanism may be defective in this disorder, and this would explain the impaired release of platelet-bound ["4C] 5-HT that we found.
We confirmed the observations of Baumgartner and Born that the aggregation of platelets by 5-HT is inhibited by their prior incubation with 5-HT (15) (16) (17) .
These authors suggested that during the preincubation period, 5-HT is transported through the membrane by receptors from which the amine then dissociates and is taken up in the storage granules. With increasing concentrations of 5-HT (see Fig. 2 ) or where the storage capacity of the platelet granules is inhibited by reserpine (16, 17) , the receptors become increasingly saturated with 5-HT and, hence, are unable to react with the second dose of this amine. Therefore, 5-HT-induced aggregation is inhibited, and this effect was more pronounced in patients with storage pool disease. The latter finding is consistent both with the previous conclusions that the platelets of these patients have a limited capacity for storing 5-HT and with the hypothesis of Baumgartner and Born that the aggregation of platelets by 5-HT is mediated by the same receptors on the plasma membrane that are involved in its uptake (15) (16) (17) .
As the role of 5-HT in hemostasis is not clear at present, the clinical significance of the abnormalities in 5-HT content, metabolism, release, and aggregation that we found in patients with storage pool disease remains to be determined. Recently, a type of platelet defect similar to that in storage pool disease has been described in an inbred strain of rat (57) . As in storage pool disease, the platelets of these rats (the fawnhooded strain) are deficient in both adenine nucleotides and 5-HT (57) . In addition, the behavior of these rats appears to be markedly different than that of other strains of this animal,2 and significant behavioral differences, evaluated by a variety of tests, have recently been documented.' Since some, but by no means all, of the patients with storage pool disease have had psychiatric problems of varying severity, it is entirely possible that biochemical abnormalities involving 5-HT in platelets may sometimes reflect abnormalities of a more general nature in both man (58) (59) (60) and experimental animals.
